# Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia

> **NCT05325645** · PHASE3 · RECRUITING · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 450 (estimated)

## Conditions studied

- Acute Schizophrenia

## Interventions

- **DRUG:** OPC-34712FUM/ Brexpiprazole fumarate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05325645
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-21
- **Primary completion:** 2026-02
- **Final completion:** 2026-03
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2025-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05325645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05325645, "Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05325645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*